CD4+ Treg Cell Identification for Inflammatory Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating inflammatory and autoimmune diseases, such as inflammatory bowel diseases, face challenges in consistently identifying and utilizing CD4+ T-regulatory cells (Tregs) due to crude analytical methods and incomplete understanding of Treg origin and function, leading to inconsistent therapeutic outcomes.
Innovation Solution
A method is developed to identify and isolate CD4+ Treg cells with specific migratory and functional characteristics suitable for cellular immunotherapy, involving analysis of samples from target tissues and lymphatic tissues to determine Treg populations that can migrate to and localize in diseased tissues, using surface and intracellular markers to select cells for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If crude analytical methods are used to identify Treg cells, then the identification process is simple, but the measurement precision and reliability of Treg cell identification are insufficient
Solution Approach 1:
The patent segments the Treg cell identification process into multiple distinct steps: (1) isolating CD4+ T cells from peripheral blood mononuclear cells, (2) staining with specific antibodies against Treg markers (FOXP3, CD25, CD127), (3) flow cytometric analysis with sequential gating strategies, and (4) functional assessment through suppression assays. This segmentation enables precise identification while maintaining manageable procedural complexity through systematic organization.
Solution Approach 2:
The patent performs preliminary actions by pre-staining cells with fluorescently labeled antibodies against surface markers (CD4, CD25) before intracellular FOXP3 staining, and by establishing reference gates from control samples before analyzing test samples. These preliminary steps ensure measurement precision is achieved through pre-established protocols and controls, reducing variability in the identification process.
2Reliability
If comprehensive analysis of Treg cell markers and functions is performed, then the reliability of Treg cell identification improves, but the time and complexity of the identification process increase
Solution Approach 1:
The patent employs periodic action through standardized flow cytometry acquisition protocols with predetermined event counts (e.g., acquiring 50,000-100,000 events), scheduled staining incubation times (e.g., 30 minutes at 4°C), and systematic gating sequences. This periodic approach ensures reliable data collection with consistent timing, reducing identification time while maintaining reliability through reproducible protocols.
Solution Approach 2:
The patent implements self-service through automated flow cytometric analysis where the instrument automatically gates cell populations based on pre-programmed parameters, automatically calculates percentages of Treg cells within gated populations, and generates standardized reports. This automation reduces manual analysis time while maintaining high reliability through consistent application of analysis criteria.
3Reliability
If specific tissue-tropic Treg cells are identified and used for therapy, then the treatment efficacy for inflammatory diseases improves, but the complexity of cell selection and preparation increases
Solution Approach 1:
The patent applies local quality by identifying and isolating Treg cells with specific tissue-homing characteristics relevant to the target disease tissue. For example, intestinal-tropic Tregs are selected by identifying cells expressing CCR9 and α4β7 integrin, while skin-tropic Tregs are identified by CXCR4 and CCR4 expression. This localized selection approach improves treatment efficacy for specific inflammatory diseases while managing selection complexity through disease-specific marker panels.
Solution Approach 2:
The patent utilizes parameter changes by adjusting the phenotypic criteria for Treg cell selection based on the specific disease indication. Different combinations of surface markers (CD45RA, CCR7, CD62L), chemokine receptors (CCR9, CXCR4, CCR4), and adhesion molecules (α4β7, CD103) are used to define Treg subsets with distinct tissue tropism. This flexible parameter adjustment enables targeted therapy while managing selection complexity through standardized flow cytometry protocols.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention relates to a method for identifying CD4+ Treg cells suitable for use as starting material in cellular immunotherapy, the method comprising i) analysing samples from target tissue A to identify CD4+ Treg cells with migratory character between the diseased tissue, collecting lymphatics, peripheral blood, distinct tissue adjacent to the diseased target tissue A and/or distinct tissue that is not vicinal though has migratory Treg communication with target tissue A, v) analysing samples from peripheral blood, tissue C, to identify CD4+ Treg cells with migratory character and/or functional character where the Treg cells are also emigrant from target tissue A, vi) analysing sample(s) from tissue compartments A and/or B and C, that are analytically or physically depleted of emigrants from thymus and/or immigrants from peripheral blood to a lymph node, to restrict analyses to CD4+ Treg cells of target tissue A origin and/or tropism, to identify emigrant CD4+ Treg cell populations of target tissue A, to identify emigrant CD4+ Treg cell populations with propensity to immigrate to target tissue A, to identify a migratory and/or functional defect in the CD4+ Treg cell population identified as expressing migratory and/or functional elements specific for target tissue A in any of tissue A, B or C, and whereby a combination of surface or intracellular markers on CD4+ Treg cells is identified, which combination identifies which surface or intracellular markers should be present and which surface markers should not be present in CD4+ Treg cell populations suitable for use as starting material in cellular immunotherapy.